Evidence map›Paper›PMID 38761294›Full record

ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2024

Safety and feasibility of intravenous sotalol loading for the prevention of ventricular arrhythmias.

Abhinav Sehgal, Arati Gangadharan, Herman A Carneiro, Graham Peigh, Jessica Charron, Graham Lohrmann, Mahmoud Elsayed, Jayson Baman, Anna Pfenniger, Kaustubha Patil and 7 more

Abstract read
In one paragraph

Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Abhinav SehgalDepartment of Medicine, Northwestern University, 251 E Huron St., Chicago, IL, 60611, USA. abhinav.sehgal@nm.org.ORCID http://orcid.org/0000-0001-7410-8768
Arati GangadharanDepartment of Medicine, Northwestern University, 251 E Huron St., Chicago, IL, 60611, USA.
Herman A CarneiroDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Graham PeighDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Jessica CharronDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Graham LohrmannDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Mahmoud ElsayedDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Jayson BamanDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Anna PfennigerDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Kaustubha PatilDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Alexandru ChicosDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Rishi AroraDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Susan S KimDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Albert LinDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Rod PassmanDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Bradley P KnightDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Nishant VermaDivision of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.

Funding

New and Disruptive Therapeutic Approaches to Target Fundamental Molecular Mechanisms Underlying Atrial FibrillationR35HL161249 · NHLBI · UNIVERSITY OF CHICAGO · PI Rishi Arora · 2022 to 2026
$5.1M
NHLBI NIH HHS R35 HL161249
6 · The paper itself

Abstract

backgroundThe use of intravenous (IV) sotalol loading following recent U.S. Food and Drug Administration (FDA) approval of a 1-day loading protocol has reduced the obligatory 3-day hospital stay for sotalol initiation when given orally. Several studies have recently demonstrated the safety and feasibility of IV loading for patients with atrial arrhythmias. However, there is a paucity of data on the feasibility and safety of IV sotalol loading for patients with ventricular arrhythmias. This study aims to assess the safety, feasibility, and length of stay (LOS) outcomes of IV sotalol loading for the prevention of ventricular arrhythmias.

methodsA retrospective analysis was performed of all patients undergoing IV sotalol loading and oral sotalol initiation for ventricular arrhythmias, or IV sotalol loading for atrial arrhythmias between August 2021 and December 2023 at Northwestern University. Baseline characteristics, success of sotalol initiation/loading, changes in heart rate (HR) and QT/QTc, safety, and LOS were compared between patients undergoing sotalol loading/initiation for ventricular arrhythmias (IV vs. PO) and between patients undergoing IV sotalol loading for ventricular arrhythmias vs. for atrial arrhythmias.

resultsA total of 28 patients underwent sotalol loading/initiation for ventricular arrhythmias (N = 15 IV and N = 13 PO) and 41 patients underwent IV sotalol loading for atrial arrhythmias. Baseline characteristics of congestive heart failure history and left ventricular ejection fraction were worse in the ventricular arrhythmias group. There was no significant difference in the successful completion of IV sotalol loading for ventricular arrhythmias compared to oral sotalol initiation for ventricular arrhythmias or IV sotalol loading for atrial arrhythmias (86.7% vs. 92.3% vs. 90.2%, p = 0.88). There was a significant increase in ΔQTc following IV sotalol infusion for ventricular arrhythmias compared to following PO sotalol initiation for ventricular arrhythmias (46.4 ± 29.2 ms vs. 8.9 ± 32.6 ms, p = 0.004) and following IV sotalol infusion for atrial arrhythmias (46.4 ± 29.2 ms vs. 24.0 ± 25.1 ms, p = 0.018). ΔHR following IV sotalol infusion for ventricular arrhythmias was similar to ΔHR following PO sotalol initiation for ventricular arrhythmias and ΔHR following IV sotalol infusion for atrial arrhythmias (- 7.5 ± 8.7 bpm vs. - 8.5 ± 13.9 bpm vs. - 8.3 ± 13.2 bpm, p = 0.87). There were no significant differences in discontinuation for QTc prolongation (6.7% vs. 1.7% vs. 2.4%, p = 0.64) and bradycardia (13.3% vs. 7.7% vs. 9.8%, p = 0.88) between IV sotalol loading for ventricular arrhythmias, PO sotalol initiation for ventricular arrhythmias, and IV sotalol loading for atrial arrhythmias. There were no instances of hypotension, life-threatening ventricular arrhythmias, heart failure, or death. Length of stay was significantly shorter for IV sotalol loading compared to PO sotalol initiation for ventricular arrhythmias (1.1 ± 0.36 days vs. 4.2 ± 1.0 days, p < 0.0001).

conclusionIV sotalol loading appears feasible and safe for use in ventricular arrhythmias and results in a decreased length of stay. Despite increased comorbidities and greater increase in QTc interval following IV sotalol infusion in the ventricular arrhythmias group, there were no significant differences in successful completion of loading or adverse outcomes when compared to PO sotalol initiation for ventricular arrhythmias and IV loading for atrial arrhythmias.

Indexed as

Anti-Arrhythmia AgentsFeasibility StudiesSotalolAdministration, IntravenousAdministration, OralAgedArrhythmias, CardiacFemaleHumansInfusions, IntravenousLength of StayMaleMiddle AgedRetrospective StudiesTachycardia, VentricularAnti-Arrhythmia AgentsSotalolAtrial arrhythmiasPremature ventricular complexSotalolVentricular arrhythmiasVentricular tachycardia

Identifiers

PMID38761294
PMCPMC12915955

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.